Clinical Trial Update: Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea [Phase 2]

View source ↗

Summary

Phase 2 trial assessing safety and efficacy of Rebamipide 2% ophthalmic suspension for dry eye, with evaluation of effects on the central cornea.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dry Eye
• Keratoconjunctivitis Sicca

Drugs mentioned

• Rebamipide 2% ophthalmic suspension (rebamipide)

Snippet

Sponsor: Kubota Vision Inc. | Conditions: Keratoconjunctivitis Sicca, Dry Eye | Phase 2 | Status: COMPLETED